MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-23-2026
Theravance Biopharma Operating Expenses 2011-2026 | TBPH
Annual Operating Expenses Theravance Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25.9 M | 28 M | 23.8 M | 32.1 M | 71.1 M | 369 M | 325 M | 298 M | 269 M | 226 M | 219 M | 240 M | 157 M | 140 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 369 M | 23.8 M | 173 M |
Quarterly Operating Expenses Theravance Biopharma
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.4 M | 28.9 M | - | 27.7 M | 30 M | 25.7 M | - | 24.5 M | 29.9 M | 35.3 M | - | 26.7 M | 34.2 M | 50.4 M | 71.1 M | 66.8 M | 77 M | 98.1 M | 95.2 M | 94.9 M | 87.2 M | 92.3 M | 100 M | 77.6 M | 68.6 M | 79 M | 78.4 M | 75.3 M | 72.2 M | 73.3 M | 83.7 M | 61.3 M | 68.6 M | 61.9 M | 63.5 M | 52.6 M | 53 M | 60.1 M | 59.7 M | 53.8 M | 52.4 M | 58.1 M | 67.2 M | 56.4 M | 59.7 M | 61 M | 44.3 M | 41.1 M | 39 M | 32.2 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 100 M | 24.5 M | 59.1 M |
Operating Expenses of other stocks in the Biotechnology industry
| Issuer | Operating Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
432 M | - | 2.43 % | $ 254 M |  Germany |
 |
Advaxis
ADXS
|
22 M | - | -9.65 % | $ 45.9 M |  USA |
 |
Akouos
AKUS
|
86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
196 M | - | - | $ 28.6 M | USA |
 |
AlloVir
ALVR
|
46.2 M | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
1.49 B | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
210 M | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
9.57 M | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
4.78 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
2.66 B | - | - | $ 40.3 B | USA |
 |
Applied Molecular Transport
AMTI
|
127 M | - | - | $ 10.1 M | USA |
 |
Applied Therapeutics
APLT
|
74.5 M | - | - | $ 8.42 M | USA |
 |
Aptorum Group Limited
APM
|
20.7 M | $ 0.88 | -2.07 % | $ 6.47 M | China |
 |
Genfit SA
GNFT
|
78.3 M | - | 2.54 % | $ 160 B |  France |
 |
ACADIA Pharmaceuticals
ACAD
|
708 M | $ 22.67 | 1.66 % | $ 3.76 B | USA |
 |
Aptinyx
APTX
|
62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.22 M | - | -1.52 % | $ 24.7 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
29.8 M | - | - | $ 7.46 M |  Israel |
 |
Brainstorm Cell Therapeutics
BCLI
|
31.7 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
106 M | - | -4.8 % | $ 255 M | USA |
 |
AIkido Pharma
AIKI
|
179 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cara Therapeutics
CARA
|
26.7 M | - | -3.03 % | $ 260 M | USA |
 |
CASI Pharmaceuticals
CASI
|
38.9 M | - | - | $ 35.4 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
629 M | - | - | - |  Russia |
 |
ChromaDex Corporation
CDXC
|
66.9 M | - | -0.88 % | $ 598 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.3 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
24.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
80 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
23.4 K | - | 17.91 % | $ 11.1 M | USA |
 |
BioNTech SE
BNTX
|
512 M | $ 102.06 | - | $ 27.2 B | Germany |
 |
Checkpoint Therapeutics
CKPT
|
56.2 M | - | - | $ 169 M | USA |
 |
Avenue Therapeutics
ATXI
|
4.49 M | - | -52.27 % | $ 4.45 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.5 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
85.5 M | $ 4.09 | -0.24 % | $ 437 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
137 M | $ 23.29 | -0.56 % | $ 2.96 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
145 M | $ 1.48 | 4.23 % | $ 394 M | Britain |
 |
Aptose Biosciences
APTO
|
24.7 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
17.6 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
71.7 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
14 M | $ 2.91 | 0.34 % | $ 4.79 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
390 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
80.2 M | - | - | $ 3.67 B | USA |
 |
Evogene Ltd.
EVGN
|
13.8 M | $ 0.79 | 1.28 % | $ 27.9 M | Israel |
 |
bluebird bio
BLUE
|
854 M | - | - | $ 546 M | USA |
 |
CureVac N.V.
CVAC
|
88.9 M | - | - | $ 867 M | Germany |
 |
ContraFect Corporation
CFRX
|
64.6 M | - | -5.16 % | $ 5.39 M | USA |
 |
Cardiff Oncology
CRDF
|
49.6 M | $ 1.68 | -2.33 % | $ 112 M | USA |
 |
CTI BioPharma Corp.
CTIC
|
47.8 M | - | - | $ 1.2 B | USA |
 |
BioXcel Therapeutics
BTAI
|
107 M | $ 1.06 | -2.75 % | $ 12.9 M | USA |